CD8A and melanoma: Previous studies have shown, in tissue samples of patients with advanced melanoma, that the degree of CD8+ T cell infiltration can adequately predict the efficacy of PD-1/PD-L1 monoclonal antibody treatment (Tumeh et al., 2014).